AOP Health presents final results from its CONTINUATION-PV study -up to 7.5 years treatment with BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera patients - at EHA 2022 Annual Meeting13. 6. 2022
AOP Health Submits New Drug Application for Landiolol, Seeking Approval in the United States2. 6. 2022
AOP Health opens its Italian base in Pisa20. 5. 2022
AOP Health team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering is of key importance for AOP Health. It allows further developing AOP Health’s rare disease and critical care portfolio and enables to approach patients beyond company’s core markets in Europe.
AOP Health team develops and investigates therapy options for patients with rare diseases and in critical conditions – commitment and appreciation are the essence of our cooperative work.